Sernova Corp. is a publicly traded (TSX-V: SVA; OTCQB: SEOVF; FSE: PSH) clinical stage regenerative medicine company commercializing technologies for patients with chronic metabolic, neurological, and hematological diseases. Insulin-dependent diabetes is our first clinical indication and pipeline indications include hemophilia, benign thyroid disease and other diseases.
Sernova’s platform technologies include the Cell Pouch System™ (CPS), a small scalable implantable medical device which provides a pre-vascularized environment for the housing and long-term survival and function of therapeutic cells including human donor and stem cell derived technologies. Our micro-encapsulation technologies within the Cell Pouch™ are expected to provide local immune protection for the therapeutic cells.
In December, 2015 the HemAcure consortium, with Sernova as member was awarded €5.6-Million (U.S. $ 6.2M) from the European Commission’s Horizon 2020 grant program for development of our hemophilia A cell based technology.
Sernova has recently also announced receiving FDA IND clearance for a US clinical trial of the Cell Pouch™ with therapeutic cells. The goal of this study is to provide type-1 diabetes patients with hypoglycemia unawareness, a novel cell therapy treatment utilizing the CPS with implanted human donor islets to reduce or eliminate the need for injections of exogenous insulin, while continuing our long-term safety assessments. Sernova is also developing stem cell based technologies to treat type-1 diabetes.